Pfizer Obligations. (a) Pfizer shall use reasonably diligent efforts to exploit Licensed Products commercially employing similar effort to that applied to other products similarly situated; provided, however, Pfizer may, in its sole, unfettered judgement, discontinue the development or sale of any Licensed Product in any country in the world or all of them.
Pfizer Obligations. 2.4.1 Pfizer shall use reasonably diligent efforts to exploit Licensed
Pfizer Obligations. 2.3.1 Pfizer shall use reasonably diligent efforts to exploit Licensed Products commercially, including conducting clinical trials and obtaining regulatory approvals.
Pfizer Obligations. 2.4.1 Pfizer shall use commercially reasonable efforts to exploit Licensed Antibody Products, including conducting clinical trials and obtaining regulatory approvals.
Pfizer Obligations. During the term of any License:
Pfizer Obligations. Except as otherwise expressly set forth herein, Pfizer shall not disclose business or financial information or customer or supplier information included in the Company’s Confidential Information that is not Collaboration IP to any Third Parties without the Company’s prior written consent (which may be withheld by the Company in the Company’s good faith, sole discretion) and Pfizer shall use such Confidential Information of the Company solely for the purposes expressly permitted hereunder. Pfizer shall protect all other Confidential Information of the Company against unauthorized uses and disclosures, and disclose to Third Parties, using the same degree of care as Pfizer uses with respect to its own similar information (which in no event shall be less than a reasonable degree of care); provided that, notwithstanding anything to the contrary in this Section 12.2, without the Company’s prior written consent (which may be withheld by the Company in the Company’s good faith, sole discretion), Pfizer shall not disclose any such Collaboration IP included in the Company’s Confidential Information to any Company Competitor for such Company Competitor to use in the Field.
Pfizer Obligations. (a) Pfizer shall use reasonably diligent efforts to exploit Licensed Products commercially employing similar effort to that applied to other products similarly situated; provided, however, Pfizer may, in its sole, unfettered judgement, discontinue the development or sale of any Licensed Product in any country in the world or all of them. (b) If Pfizer grants a sublicense pursuant to this Section 5, Pfizer shall guarantee that any sublicensee fulfills all of Pfizer's obligations under this Agreement; PROVIDED, HOWEVER, that Pfizer shall not be relieved of its obligations pursuant to this Agreement. 5.3.5
Pfizer Obligations. Pfizer will send Pfizer Materials described below to Xenogen Biosciences for performance of this Agreement. Pfizer will deliver to Xenogen Biosciences targeted ES cell lines *** in tubes containing approximately *** cells/vial. The ES cell lines will have been tested by karyotype analysis and for MAP and mycoplasma prior to shipment to Xenogen Biosciences. These reagents will be sent on dry ice. In addition, Pfizer shall provide sequence information of genomic and targeting vectors and PCR primers. All of the foregoing should be sent to the following address: Xenogen Biosciences 0 Xxxxx Xxxxx Xxxxx Xxxxxxxx, XX 00000 Attn: Dr. Xxx Xxxxxxxx
Pfizer Obligations. Pfizer will send Pfizer Materials described below to Xenogen Biosciences for performance of this Agreement. Pfizer will deliver to Xenogen Biosciences targeted ES cell lines *** in tubes containing approximately two million (2X106) cells/vial. The ES cell lines will have been tested by karyotype analysis and for MAP and mycoplasma prior to shipment to Xenogen Biosciences. These reagents will be sent on dry ice. In addition, Pfizer shall provide sequence information of genomic and targeting vectors and PCR primers. All of the foregoing should be sent to the following address: Xenogen Biosciences 0 Xxxxx Xxxxx Xxxxx Xxxxxxxx, XX 00000 Attn: Dr. Xxx Xxxxxxxx Xenogen Cranbury Obligations Phase 1: Microinjection of homologous recombinant ES cell clones and identification of chimeras. The scope of Xenogen Biosciences’ obligations under Phase 1 of this Protocol is: (i) preparation and injection of each targeted ES clone into up to *** blastocysts and transfer of injected blastocysts into pseudo-pregnant females for generation and identification of *** chimeras. Duration: eight to ten (8-10) weeks after Pfizer’s delivery of Pfizer Materials.
Pfizer Obligations. 2.3.1 Pfizer shall use reasonably diligent efforts to exploit Products commercially, including, without limitation, conducting clinical trials and obtaining regulatory approvals. 3 2.3.2 If Pfizer grants a sublicense pursuant to Section 2, Pfizer shall guarantee that any sublicensee fulfills all of Pfizer's obligations under this Agreement; provided, however, that Pfizer shall not be relieved of its obligations pursuant to this Agreement. 2.4
